Knockdown of Tyrosine Kinase Receptor FGFR1 via AZD4547 Suppresses Breast Cancer Proliferation, Migration, and Invasion in BRCA1 Mutant Adipose-Derived Stem Cells (ASCs) via IL-6 and TNF-α Modulation

Read full text Summarise with VIRAT
Authors: Nahid Sabah aldin Saber, Zahraa Ali Mohammed
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Breast cancer is a complex heterogeneous disease that poses significant challenges in identifying novel therapeutic strategies and new therapeutic targets. Recent research has identified adipose-derived stem cells (ASCs) role in the progression of small tumors. Mutations in Breast Cancer gene 1 (BRCA1) are known to play a crucial role in DNA repair and cell cycle regulation. BRCA1 mutations have been associated with increased risks of breast and ovarian cancer. Moreover, studies have shown that Fibroblast Growth Factor Receptor 1 (FGFR1) is involved in initiation of many cancers, including breast cancer. In the present study, we aim to investigate the role of FGFR1 in BRCA1-negative ASCs and its therapeutic potential in breast cancer. Using AZD4547 to knockdown FGFR1 expression in BRCA1 mutant ASCs in vitro and in vivo. Our results showed that FGFR1 knockdown significantly inhibited the release of pro-inflammatory cytokines, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α ) from BRCA1 mutant ASCs. Furthermore, FGFR1 knockdown has significantly decreased proliferation, migration, and invasion of breast cancer cells co-cultured with BRCA1 mutant ASCs. Xenograft studies have confirmed reduced tumor growth and metastasis via Vascular Endothelial Growth Factor A (VEGFA) expression inhibition and Nuclear factor kappa-B cells (NF-κ B) pathway downregulation. Collectively, our results emphasize the critical role of FGFR1 in BRCA1 mutant ASCs in the progression of breast cancer through inflammatory cytokines regulation. Moreover, our results suggest that targeting FGFR1 in tumor microenvironment, specifically in BRCA1 mutant ASCs, may be a promising therapeutic approach in breast cancer treatment. However, further clinical studies are needed.

Fields of Study & Subjects

Fibroblast Growth Factor Research Cancer Cells and Metastasis Angiogenesis and VEGF in Cancer

Publication details

Journal / source
Baghdad Science Journal
Volume
23
Issue
3
Pages
807–817
Publication date
20 March 2026
Language
EN